Methods for treating T lymphocyte mediated diseases

Abstract

The present invention relates to the field of medicine and more specifically to a method for treating diseases or conditions mediated by T lymphocytes carrying a TRBV9 segment in a T cell receptor, comprising administering an anti-TRBV9 antibody in a specific dose and dosing regimen, and further to the use of an anti-TRBV9 antibody to treat a disease or disorder mediated by T lymphocytes carrying a TRBV9 segment in a T cell receptor, wherein the anti-TRBV9 antibody is administered in a specific dose and dosage regimen.

Description

Field of the Invention

[0001] The present invention relates to the field of medicine, and more particularly to methods for treating diseases or disorders mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprise administering an anti-TRBV9 antibody using defined dosages and dosing regimens; and to the use of an anti-TRBV9 antibody for treating diseases or disorders mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered using defined dosages and dosing regimens. Background of the Invention

[0003] Autoimmune diseases are caused by autoreactive T lymphocytes (Haroon N et al., Arthritis Rheum. October 2013; 65(10):2645 - 54., Duarte J. et al., PloS One May 10, 2010; 5(5):e10558; Konig M. et al., Front Immunol January 25, 2016; 7:11). A major role in the emergence of autoreactive T lymphocyte clones is played by the interaction of the antigen - recognizing T cell receptor (TCR) with proteins of the major histocompatibility complex (MHC, HLA), which present processed peptides of intracellular proteins or peptides of proteins of pathogenic organisms on their surface. Many autoimmune diseases are associated with the presence of certain variants of HLA genes in humans. Accordingly, the HLA - B27 allele is associated with ankylosing spondylitis, reactive arthritis, and Crohn's disease. The risk of developing autoimmune diseases in carriers of certain HLA allele variants can be explained by the fact that these alleles preferentially present certain peptides that are self - antigens, and the immune response against these peptides triggers the development of autoimmune diseases. One of the possible underlying mechanisms of the autoimmune response is the presentation, by histocompatibility complex molecules, of peptides of proteins of bacterial or viral origin that are homologous to peptides of the organism itself, and as a result of cross - reactivity, this fact may lead to an immune response against self - antigens.

[0004] The prior art provides that T cell receptor (TCR) sequences are markers that allow the identification of T lymphocyte clones involved in the pathogenesis of autoimmune diseases. The T cell receptor subunits structurally belong to the immunoglobulin superfamily and are formed by several gene segments. The variable region of the TCR forms the antigen - binding center of the TCR. This means that they are clone - specific, i.e., they are different in those T lymphocytes that react against different antigens.

[0005] When an antigen binds to its T cell receptor (TCR), the T lymphocyte (T cell) is stimulated. The TCR, a defining structure of T cells, is a transmembrane heterodimer composed of an α-chain and a β-chain or a δ-chain and a γ-chain linked by disulfide bonds. Within these chains are complementarity-determining regions (CDRs), which determine the antigen to which the TCR will bind. TCR development occurs through a lymphocyte-specific gene recombination process that assembles the final sequence from a large number of potential segments. This genetic recombination of TCR gene segments in somatic T cells occurs during the early stages of thymic development. The locus of the TCRα gene contains variable (V) and joining (J) gene segments (Vβ and Jβ), while the TCRβ locus contains a D gene segment in addition to the Vα and Jα segments. Accordingly, the α-chain is generated by VJ recombination, and the β-chain involves VDJ recombination.

[0006] The locus of the TCRα-chain gene consists of 46 variable segments (TRAV), 8 joining segments (TRAJ), and a constant region. The locus of the TCRβ-chain gene consists of 48 variable segments (TRBV), followed by two diversity segments (TRBD), 12 joining segments (TRBJ), and two constant regions. (Bio-Rad. Mini-review|An overview of T cell receptors[Electronic resource] / / Bio-Rad.URL:https: / / www.bio-rad-antibodies.com / t-cell-receptor-minireview.html(Accessed: April 24, 2020)).

[0007] To date, a large amount of data has been accumulated, confirming that the development of HLA-B27-related diseases is due to the expansion of antigen-specific T lymphocyte clones.

[0008] A common variant of the autoimmune TCR has been described in ankylosing spondylitis (radiologically positive axial spondyloarthritis); it has been shown to be present in the synovial fluid and peripheral blood of patients with ankylosing spondylitis regardless of the HLA*B27 allele status and not present in healthy donors at the same depth of analysis (Faham Μ. et al., Arthritis Rheumatol. 2017;69(4):774 - 784; Komech E et al 12th EJI-EFIS Tatra Immunology Conference; September 3 - 7, 2016; Strbske Pleso, Slovakia. Abstract book page 39). The TCR belongs to the TRBV9 family (according to IMGT nomenclature).

[0009] It has been shown that T cell receptors carrying the β-chain of the TRBV9 family are also involved in the development of such autoimmune diseases as celiac disease (Petersen J et al., J Immunol. 2015; 194(12): 6112-22). They have also been found on the surface of malignant T cells in T cell lymphomas and T cell leukemias, including T cell lymphomas caused by Epstein-Barr virus (EBV) (Toyabe S et al., Clin Exp Immunol. 2003; 134(1): 92-97).

[0010] Taking the above into consideration, the TRBV9 protein may serve as a target for cytotoxic monoclonal antibodies that will induce the depletion of TRBV9+ T lymphocytes (TRBV9-positive T lymphocytes), including pathogenic autoreactive T lymphocyte clones.

[0011] Accordingly, there is a need to develop methods for treating diseases or disorders mediated by human T cell receptors carrying TRBV9, which include administering anti-TRBV9 antibodies using defined dosages and dosing regimens. Brief Description of the Drawings

[0013] Figure 1 is a diagram of the main processes considered in the mathematical model

[0014] TCR - T cell receptor,

[0015] Effector cell - effector cell. Detailed Description of the Invention

[0017] Definition

[0018] Unless otherwise defined herein, all technical and scientific terms used in connection with the present invention will have the same meaning as commonly understood by one of ordinary skill in the art.

[0019] In addition, unless the context otherwise requires, singular terms shall include plural terms and plural terms shall include singular terms.

[0020] As used in this specification and the claims that follow, unless the context requires otherwise, the words "have", "include", and "comprise" or variations thereof such as "has", "having", "includes", "including", "comprises", or "comprising" shall be understood to imply the inclusion of the stated integer or group of integers but not the exclusion of any other integer or group of integers.

[0021] The term "antibody" or "immunoglobulin" (Ig) includes full-length antibodies or any antigen-binding fragment thereof (i.e., "antigen-binding portion") or its individual chains. The term "antibody" as used within the scope of the present invention is used in the broadest sense and may include, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, humanized, fully human, and chimeric antibodies.

[0022] A full-length antibody is a glycoprotein that comprises at least two heavy (H) chains and two light (L) chains that are inter-connected by disulfide bonds. Each heavy chain comprises a heavy-chain variable region (abbreviated herein as VH) and a heavy-chain constant region. The constant region is the same for all antibodies of the same isotype, but different for antibodies of different isotypes. Heavy chains γ, α, and δ have a constant region composed of three constant domains CH1, CH2, and CH3 (in a straight line), and a hinge region for increased flexibility (Woof J., Burton D., Nat Rev Immunol 4, 2004, pp. 89-99). In mammals, only two types of light chains are known, designated lambda (λ) and kappa (κ). Each light chain consists of a light-chain variable region (abbreviated herein as VL) and a light-chain constant region. The approximate length of a light chain is 211 to 217 amino acids. Preferably, the light chain is a lambda (λ) light chain, and the constant domain CL is preferably C lambda (λ).

[0023] The VL and VH regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), which are located between more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with an antigen. The constant region of an antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system (C1q).

[0024] As used herein, the term "antigen-binding portion" or "antigen-binding fragment" of an antibody refers to one or more antibody fragments that retain the ability to specifically bind an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. As used in the present invention, the term "antigen-binding fragment" means a Fab fragment, i.e., a monovalent fragment consisting of the VL, VH, CL, and CH1 domains, which is linked to a monomer of the Fc fragment.

[0025] The term "variable" refers to the fact that certain portions of the variable domains vary extensively in sequence among antibodies. The V domains mediate antigen binding and determine the specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions are composed of invariant segments of 15-30 amino acids called framework regions (FRs), which are separated by shorter regions of extreme variability called "hypervariable regions" or CDRs. The variable domains of the native heavy and light chains each contain four FRs that largely adopt a β-sheet conformation and are linked by three hypervariable regions, which form loops connecting the β-sheet structures and in some cases form part of the β-sheet structures. The hypervariable regions in each chain are held tightly together by the FRs and, together with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of the antibody (see Kabat et al., Sequences of Proteins of Immunological Interest. 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not directly involved in antibody-antigen binding but exhibit various effector functions, such as the participation of antibodies in antibody-dependent cell-mediated cytotoxicity (ADCC).

[0026] According to the present specification, the term "hypervariable region" refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable regions generally contain amino acid residues from "complementary determining regions" or "CDRs" and / or those from "hypervariable loops".

[0027] The "Kabat numbering scheme" or "numbering according to Kabat" in the present invention refers to a system for numbering amino acid residues that are more variable (i.e., hypervariable) than other amino acid residues in the variable regions of the heavy and light chains of an antibody (Kabat et al., Ann. N.Y. Acad. Sci., 190:382-93 (1971); Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., U.S. Department of Health and Human Services, NIH Publication No. 91-3242 (1991)).

[0028] An antibody of the present invention that "binds" to a target antigen refers to an antibody that binds to the antigen with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent for targeting proteins or cells or tissues that express the antigen, and that cross-reacts slightly with other proteins. According to the assay method: fluorescence-activated cell sorting (FACS), radioimmunoassay (RIA), or ELISA, in such embodiments, the binding of the antibody to a non-target protein is less than 10% of the binding of the antibody to the specific target protein. With respect to the binding of an antibody to a target molecule, the term "specifically binds" or the phrase "binds specifically to" or "is specific for an epitope on a particular polypeptide or a particular target polypeptide" means a binding that is significantly (measurably) different from non-specific interactions.

[0029] Specific binding can be measured, for example, by determining the molecular binding compared to the binding to a control molecule. For example, specific binding can be determined by competition with another molecule that is similar to the target, e.g., an excess of unlabeled target. In such a case, if the binding of the labeled target to the probe is competitively inhibited by the excess unlabeled target, specific binding is indicated. As used in this specification, the term "specifically binds" or the phrase "binds specifically to" or "is specific for an epitope on a particular polypeptide or a particular target polypeptide" can be described by examples of molecules having the following KD (affinity constant) for the target: at least about 200 nM, or at least about 150 nM, or at least about 100 nM, or at least about 60 nM, or at least about 50 nM, or at least about 40 nM, or at least about 30 nM, or at least about 20 nM, or at least about 10 nM, or at least about 8 nM, or at least about 6 nM, or at least about 4 nM, or at least about 2 nM, or at least about 1 nM or greater. In one embodiment, the term "specifically binds" refers to a binding in which a molecule binds to a particular polypeptide or an epitope on a particular polypeptide and binds substantially not to any other polypeptide or epitope on a polypeptide.

[0030] The term "monoclonal antibody" or "mAb" refers to an antibody synthesized and isolated as a single clone population of cells.

[0031] The term "recombinant antibody" refers to an antibody expressed in a cell or cell line containing a nucleotide sequence encoding the antibody, wherein the nucleotide sequence is not naturally related to the cell.

[0032] The term "isolated", as applied to describe the various antibodies according to the present invention, refers to an antibody that has been identified and separated and / or regenerated from the cells or cell culture in which it is expressed. Impurities (contaminant components) from the natural environment are materials that typically interfere with the diagnostic or therapeutic use of the polypeptide and may include enzymes, hormones, and other protein or non-protein solutes. Isolated polypeptides are generally prepared by at least one purification step.

[0033] The terms "anti-TRBV9 antibody", "antibody against TRBV9", "antibody specifically binding to the β-chain of the TRBV9 family", and "antibody against the β-chain of the TRBV9 family" are interchangeable within the scope of the present invention and refer to an antibody that specifically binds to an epitope of the β-chain of the human T cell receptor TRBV9 family.

[0034] The term "primary dose" refers to the recommended dose of an anti-TRBV9 antibody product, or the full recommended dose of an anti-TRBV9 antibody product, or the recommended dose of an anti-TRBV9 antibody product in the form of an intravenous infusion, or the full recommended dose of an anti-TRBV9 antibody product in the form of an intravenous infusion.

[0035] The term "half of the primary dose" refers to half of the recommended dose of an anti-TRBV9 antibody product, or half of the full recommended dose of an anti-TRBV9 antibody product, or half of the recommended dose of an anti-TRBV9 antibody product in the form of an intravenous infusion, or half of the full recommended dose of an anti-TRBV9 antibody product in the form of an intravenous infusion.

[0036] In the context of administration, the term "at least" refers to a minimum administration interval of ±2 days. "At least 3 months" refers to administration after 3 months ±2 days, or 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days, etc., in increments of 3 months ±2 days. "At least 6 months" refers to administration after 6 months ±2 days, or 9 months ±2 days, or 12 months ±2 days, etc., in increments of 3 months ±2 days. "At least 9 months" refers to administration after 9 months ±2 days, or 12 months ±2 days, or 15 months ±2 days, etc., in increments of 3 months ±2 days. "At least 12 months" refers to administration after 12 months ±2 days, or 15 months ±2 days, or 18 months ±2 days, etc., in increments of 3 months ±2 days.

[0037] The term "administration interval" refers to the time interval between administrations, and subsequent administrations are counted starting from the date of the second or third infusion, and subsequently from each previous administration.

[0038] The term "first administration" or "first infusion" refers to the initial dose or half of the main dose of the anti-TRBV9 antibody product.

[0039] The term "second administration" or "second infusion" refers to the administration of the main dose of the anti-TRBV9 antibody product at least 3 months after the first administration.

[0040] The term "third administration" or "third infusion" refers to the administration of the main dose of the anti-TRBV9 antibody product at least 3 months after the second administration.

[0041] The term "subsequent administration" refers to the administration of the main dose of the anti-TRBV9 antibody product at least 3 months after each previous administration.

[0042] The term "use" applies to the possibility of using the anti-TRBV9 antibody according to the present invention or a pharmaceutical composition containing the same for treating a disease or disorder, alleviating the course of the disease or disorder, accelerating the remission of the disease or disorder, or reducing the recurrence rate of the disease or disorder.

[0043] The term "disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor" refers to any disease or disorder directly or indirectly associated with T lymphocytes carrying the TRBV9 segment in the T cell receptor, including the etiology, development, progression, persistence, or pathological state of the disease or disorder.

[0044] The term "treatment method" applies to the ability to use the antibody of the present invention or a pharmaceutical composition containing the same to treat a disease or disorder, alleviate the course of the disease, accelerate the remission of the disease or disorder, or reduce the recurrence rate of the disease or disorder, wherein the disease or disorder is related to the activity of T lymphocytes carrying the TRBV9 segment in the T cell receptor. "Treat" or "treatment" of a disease, disorder, or condition may include preventing or delaying the appearance of clinical symptoms of a disease, disorder, or condition that develops in humans, inhibiting the disease, disorder, or condition, i.e., stopping, reducing, or delaying the development of the disease or its recurrence (in the case of maintenance treatment) or at least one of its clinical or subclinical symptoms, or alleviating or moderating the disease, i.e., causing the regression of the disease, disorder, or condition. As used herein, "alleviating" a disease, disorder, or condition means reducing the severity and / or frequency of occurrence of the symptoms of the disease, disorder, or condition.

[0045] The present invention discloses a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering an anti-TRBV9 antibody using a defined dosage and dosing regimen. In addition, the present invention discloses the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered using a defined dosage and dosing regimen.

[0046] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03 - 10 mg / kg.

[0047] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03 - 7 mg / kg.

[0048] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.3 - 7 mg / kg.

[0049] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 1 - 7 mg / kg.

[0050] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 2 - 7 mg / kg.

[0051] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 3 - 7 mg / kg.

[0052] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 4 - 7 mg / kg.

[0053] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 5 - 7 mg / kg.

[0054] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 6 - 7 mg / kg.

[0055] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0056] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0057] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 - 12 months.

[0058] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 - 12 months.

[0059] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 6 - 12 months.

[0060] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 6 - 12 months.

[0061] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 months; or the anti-TRBV9 antibody is administered at least once every 6 months; or the anti-TRBV9 antibody is administered at least once every 9 months; or the anti-TRBV9 antibody is administered at least once every 12 months.

[0062] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 months; or the anti-TRBV9 antibody is administered once every 6 months; or the anti-TRBV9 antibody is administered once every 9 months; or the anti-TRBV9 antibody is administered once every 12 months.

[0063] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 75 - 675 mg.

[0064] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 100 - 650 mg.

[0065] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody in a dose of 75 - 175 mg; or 200 - 300 mg; or 325 - 425 mg; or 450 - 650 mg; or 575 - 675 mg.

[0066] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering to a subject in need thereof an anti-TRBV9 antibody in a dose of 100 - 150 mg; or 225 - 275 mg; or 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg.

[0067] In some embodiments of the present invention, the anti-TRBV9 antibody is administered in a dose of 115 - 135 mg; or 240 - 260 mg; or 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg.

[0068] In some embodiments of the present invention, the anti-TRBV9 antibody is administered in a dose of 120 - 130 mg; or 245 - 255 mg; or 370 - 380 mg; or 495 - 505 mg; or 620 - 630 mg.

[0069] In some embodiments of the present invention, the anti-TRBV9 antibody is administered in a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0070] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 - 12 months.

[0071] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 - 12 months.

[0072] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 6 - 12 months.

[0073] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 6 - 12 months.

[0074] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 months; or at least once every 6 months; or at least once every 9 months; or at least once every 12 months.

[0075] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 months; or once every 6 months; or once every 9 months; or once every 12 months.

[0076] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg at least once every 6 months.

[0077] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0078] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0079] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 9 months; or once every 12 months.

[0080] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 12 months.

[0081] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg at least once every 6 months.

[0082] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0083] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0084] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 9 months; or once every 12 months.

[0085] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 12 months.

[0086] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg at least once every 6 months.

[0087] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0088] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0089] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 9 months; or once every 12 months.

[0090] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 12 months.

[0091] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg at least once every 6 months.

[0092] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0093] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0094] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 9 months; or once every 12 months.

[0095] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 12 months.

[0096] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least once every 6 months.

[0097] In some embodiments, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0098] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0099] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 9 months; or once every 12 months.

[0100] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 12 months.

[0101] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg at least once every 6 months.

[0102] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0103] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0104] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 9 months; or once every 12 months.

[0105] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 12 months.

[0106] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg at least once every 6 months.

[0107] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0108] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 6 months; or every 9 months; or every 12 months.

[0109] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 9 months; or every 12 months.

[0110] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0111] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg at least every 6 months.

[0112] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0113] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 6 months; or every 9 months; or every 12 months.

[0114] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 9 months; or every 12 months.

[0115] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0116] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg at least every 6 months.

[0117] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0118] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 6 months; or every 9 months; or every 12 months.

[0119] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 9 months; or every 12 months.

[0120] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0121] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg at least every 6 months.

[0122] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0123] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 6 months; or every 9 months; or every 12 months.

[0124] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 9 months; or every 12 months.

[0125] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0126] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg at least every 6 months.

[0127] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0128] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 6 months; or every 9 months; or every 12 months.

[0129] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 9 months; or every 12 months.

[0130] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0131] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg at least every 6 months.

[0132] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0133] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 6 months; or every 9 months; or every 12 months.

[0134] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 9 months; or every 12 months.

[0135] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0136] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 8 mg / kg.

[0137] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 8 mg / kg.

[0138] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody every 9 months; or every 12 months at a dose of 8 mg / kg.

[0139] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody every 12 months at a dose of 8 mg / kg.

[0140] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 9 mg / kg.

[0141] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 9 mg / kg.

[0142] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody every 9 months; or every 12 months at a dose of 9 mg / kg.

[0143] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 12 months.

[0144] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 10 mg / kg.

[0145] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at a dose of 10 mg / kg.

[0146] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody every 9 months; or every 12 months at a dose of 10 mg / kg.

[0147] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody every 12 months at a dose of 10 mg / kg.

[0148] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg at least every 6 months.

[0149] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg every 6 months; or every 9 months; or every 12 months.

[0150] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg every 6 months; or every 9 months; or every 12 months.

[0151] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg every 9 months; or every 12 months.

[0152] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg every 12 months.

[0153] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which includes a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg at least every 6 months.

[0154] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg every 6 months; or every 9 months; or every 12 months.

[0155] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg every 6 months; or every 9 months; or every 12 months.

[0156] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg every 9 months; or every 12 months.

[0157] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg every 12 months.

[0158] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least every 6 months.

[0159] In some embodiments of the present invention, the method comprises (i) a first administration of an anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 6 months; or

[0160] (ii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 9 months; or

[0161] (iii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months; or

[0162] (iv) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 6 months; or

[0163] (v) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 9 months; or

[0164] (vi) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months; or

[0165] (vii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, and after 9 months, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 9 months; or

[0166] (viii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, and after 9 months, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months; or

[0167] (ix) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, and after 12 months, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months.

[0168] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, and after at least 3 months, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least every 6 months.

[0169] In some embodiments of the present invention, the method comprises (i) a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 6 months; or

[0170] (ii) a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 9 months; or

[0171] (iii) a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months; or

[0172] (iv) a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 6 months; or

[0173] (v) a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 9 months; or

[0174] (vi) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months; or

[0175] (vii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 9 months; or

[0176] (viii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months; or

[0177] (ix) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months.

[0178] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least once every 6 months.

[0179] In some embodiments, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises (i) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 6 months; or

[0180] (ii) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 9 months; or

[0181] (iii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 12 months; or

[0182] (iv) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 6 months; or

[0183] (v) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 9 months; or

[0184] (vi) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg six months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 12 months; or

[0185] (vii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg nine months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 9 months; or

[0186] (viii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg nine months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 12 months; or

[0187] (ix) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg. After 12 months, the second administration of the anti-TRBV9 antibody is at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg. And subsequent administrations of the anti-TRBV9 antibody are at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months.

[0188] In some embodiments of the present invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 6 months.

[0189] In some embodiments of the present invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0190] In some embodiments of the present invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0191] In some embodiments of the present invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0192] In some embodiments of the present invention, the method comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0193] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every 6 months.

[0194] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0195] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0196] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0197] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0198] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every 6 months.

[0199] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0200] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 6 months; or once every 9 months; or once every 12 months.

[0201] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 9 months; or once every 12 months.

[0202] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 12 months.

[0203] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least once every 6 months.

[0204] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 6 months; or once every 9 months; or once every 12 months.

[0205] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 6 months; or once every 9 months; or once every 12 months.

[0206] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0207] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0208] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least every 6 months.

[0209] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0210] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0211] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0212] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0213] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every 6 months.

[0214] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0215] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0216] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0217] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0218] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least once every 6 months.

[0219] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 6 months; or once every 9 months; or once every 12 months.

[0220] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 6 months; or once every 9 months; or once every 12 months.

[0221] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 9 months; or once every 12 months.

[0222] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0223] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least once every 6 months.

[0224] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0225] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0226] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 9 months; or once every 12 months.

[0227] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0228] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least once every 6 months.

[0229] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 6 months; or once every 9 months; or once every 12 months.

[0230] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 6 months; or once every 9 months; or once every 12 months.

[0231] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 9 months; or once every 12 months.

[0232] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0233] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every 6 months.

[0234] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0235] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0236] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 9 months; or every 12 months.

[0237] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 12 months.

[0238] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least every 6 months.

[0239] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0240] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 6 months; or every 9 months; or every 12 months.

[0241] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 9 months; or every 12 months.

[0242] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0243] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every 6 months.

[0244] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0245] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0246] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0247] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0248] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 6 months.

[0249] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0250] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0251] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0252] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0253] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 6 months.

[0254] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0255] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0256] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0257] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0258] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 6 months.

[0259] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0260] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0261] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0262] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0263] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 6 months.

[0264] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0265] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0266] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0267] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0268] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 6 months.

[0269] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0270] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0271] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0272] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0273] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 6 months.

[0274] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0275] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0276] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 9 months; or every 12 months.

[0277] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0278] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg at least every 12 months.

[0279] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg every 12 months.

[0280] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, [] a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg every 12 months.

[0281] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 12 months.

[0282] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg once every 12 months.

[0283] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which includes a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg at least once every 12 months.

[0284] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 12 months.

[0285] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg once every 12 months.

[0286] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg once every 12 months.

[0287] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 7 mg / kg once every 12 months.

[0288] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 0.3 - 10 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a main dose of 0.3 - 10 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.3 - 10 mg / kg at least once every 12 months.

[0289] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 12 months.

[0290] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 12 months.

[0291] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 12 months.

[0292] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg once every 12 months.

[0293] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg at least once every 12 months.

[0294] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 12 months.

[0295] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 6 months later, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 12 months.

[0296] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 9 months later, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg once every 12 months.

[0297] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg every 12 months.

[0298] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least every 12 months.

[0299] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg every 12 months.

[0300] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg every 12 months.

[0301] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 12 months.

[0302] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg once every 12 months.

[0303] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg at least once every 12 months.

[0304] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 12 months.

[0305] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg once every 12 months.

[0306] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0307] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg every 12 months.

[0308] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg at least every 12 months.

[0309] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0310] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0311] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0312] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg every 12 months.

[0313] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg at least every 12 months.

[0314] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0315] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg every 12 months.

[0316] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg once every 12 months.

[0317] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 1.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg once every 12 months.

[0318] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg at least once every 12 months.

[0319] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg once every 12 months.

[0320] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg once every 12 months.

[0321] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0322] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 4 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 4 mg / kg every 12 months.

[0323] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg at least every 12 months.

[0324] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0325] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg every 12 months.

[0326] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 9 months, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg once every 12 months.

[0327] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 2.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg once every 12 months.

[0328] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg at least once every 12 months.

[0329] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 3 months, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg once every 12 months.

[0330] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 6 months, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg once every 12 months.

[0331] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 9 months, and a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0332] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 3 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 6 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 6 mg / kg every 12 months.

[0333] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg at least every 12 months.

[0334] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 3 months, and a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0335] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 6 months, and a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg every 12 months.

[0336] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 9 months, or a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg once every 12 months.

[0337] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg once every 12 months.

[0338] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody performed at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody performed at a dose of 8 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody once every 6 months; or once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0339] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody once every 6 months; or once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0340] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0341] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 8 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody once every 12 months at a dose of 8 mg / kg.

[0342] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0343] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 6 months; or every 9 months; or every 12 months.

[0344] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 9 months; or every 12 months.

[0345] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 4.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 9 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 9 mg / kg every 12 months.

[0346] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0347] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0348] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 9 months, and then once every 9 months; or subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg once every 12 months.

[0349] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 10 mg / kg after 12 months, and then subsequent administrations of the anti-TRBV9 antibody at a dose of 10 mg / kg once every 12 months.

[0350] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg at least once every 12 months.

[0351] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 3 months, a third administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 12 months.

[0352] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after []6 months, a third administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 12 months.

[0353] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg after 9 months; or a third administration of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg once every 12 months.

[0354] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg after 12 months, a third administration of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 325 - 675 mg once every 12 months.

[0355] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg at least once every 12 months.

[0356] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 3 months; or after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg once every 12 months.

[0357] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg once every 12 months.

[0358] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 9 months; or a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg once every 12 months.

[0359] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 12 months, a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 650 mg once every 12 months.

[0360] In one aspect, the present invention relates to a method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 12 months.

[0361] In some embodiments of the present invention, the method comprises (i) a first administration of an anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, a third administration of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a primary dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months, or

[0362] (ii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months, or

[0363] (iii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months, or

[0364] (iv) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months, or

[0365] (v) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months, or

[0366] (vi) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months, or

[0367] (vii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months, or

[0368] (viii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months, or

[0369] (ix) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months.

[0370] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after at least 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least every 12 months.

[0371] In some embodiments of the present invention, the method comprises (i) the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months, or

[0372] (ii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg once every 12 months, or

[0373] (iii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg once every 12 months, or

[0374] (iv) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg once every 12 months, or

[0375] (v) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to subjects in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg once every 12 months, or

[0376] (vi) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months, or

[0377] (vii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months, or

[0378] (viii) The first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months, or

[0379] (ix) The anti-TRBV9 antibody is administered for the first time to a subject in need thereof at a dose of 115 - 135 mg; or 240 - 260 mg. After 12 months, the anti-TRBV9 antibody is administered for the second time at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg. After 12 months, the anti-TRBV9 antibody is administered for the third time at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 12 months.

[0380] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises administering the anti-TRBV9 antibody for the first time to a subject in need thereof at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg. After at least 3 months, the anti-TRBV9 antibody is administered for the second time at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg. After at least 6 months, the anti-TRBV9 antibody is administered for the third time at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least every 12 months.

[0381] In one aspect, the present invention relates to a method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, which comprises (i) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 3 months, a third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 12 months, or

[0382] (ii) a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 3 months, a third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg once every 12 months, or

[0383] (iii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 3 months, the third administration of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months, and subsequent administrations of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0384] (iv) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, the third administration of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, and subsequent administrations of the main dose of the anti-TRBV9 antibody at 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0385] (v) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0386] (vi) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 6 months, the third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0387] (vii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0388] (viii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, the third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months, or

[0389] (ix) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg. The second administration of the anti-TRBV9 antibody at the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg is after 12 months. The third administration of the anti-TRBV9 antibody at the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg is after 12 months. And subsequent administrations of the anti-TRBV9 antibody at the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg are every 12 months.

[0390] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 12 months.

[0391] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 3 months; a third administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0392] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; a third administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; or after 9 months; or after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0393] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 9 months; after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0394] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0395] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 375 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least once every 12 months.

[0396] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 3 months; after 6 months; or after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0397] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 6 months; after 6 months; or after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0398] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 9 months; after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0399] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0400] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 380 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every 12 months.

[0401] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 380 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0402] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 380 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0403] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 380 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0404] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0405] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 370 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least once every 12 months.

[0406] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 3 months later; a third administration of the anti-TRBV9 antibody at a dose of 370 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0407] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 6 months later; a third administration of the anti-TRBV9 antibody at a dose of 370 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0408] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 9 months later; a third administration of the anti-TRBV9 antibody at a dose of 370 mg 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0409] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 370 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0410] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 375 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least once every 12 months.

[0411] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 3 months later; a third administration of the anti-TRBV9 antibody at a dose of 375 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0412] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 6 months later; a third administration of the anti-TRBV9 antibody at a dose of 375 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0413] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 9 months later; a third administration of the anti-TRBV9 antibody at a dose of 375 mg 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0414] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 375 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0415] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 380 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least once every 12 months.

[0416] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg 3 months later; a third administration of the anti-TRBV9 antibody at a dose of 380 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 12 months.

[0417] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg 6 months later; a third administration of the anti-TRBV9 antibody at a dose of 380 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 12 months.

[0418] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg 9 months later; a third administration of the anti-TRBV9 antibody at a dose of 380 mg 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 12 months.

[0419] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 380 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg once every 12 months.

[0420] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 495 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least once every 12 months.

[0421] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 3 months later; a third administration of the anti-TRBV9 antibody at a dose of 495 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0422] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 6 months later; a third administration of the anti-TRBV9 antibody at a dose of 495 mg 6 months later; or 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0423] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 9 months later; a third administration of the anti-TRBV9 antibody at a dose of 495 mg 9 months later; or 12 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0424] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg 12 months later, a third administration of the anti-TRBV9 antibody at a dose of 495 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0425] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 500 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least once every 12 months.

[0426] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0427] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0428] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0429] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0430] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least once every 12 months.

[0431] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0432] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; after 6 months; or after 9 months; or after 12 months; and a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0433] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; after 9 months; or after 12 months; and a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0434] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0435] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 495 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least once every 12 months.

[0436] In some embodiments of the present invention, the method comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 3 months; after 6 months; or after 9 months; or after 12 months; and a third administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0437] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0438] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0439] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0440] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 500 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least once every 12 months.

[0441] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0442] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0443] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0444] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0445] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least once every 12 months.

[0446] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0447] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0448] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0449] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 12 months.

[0450] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least once every 12 months.

[0451] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 12 months.

[0452] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 12 months.

[0453] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 12 months.

[0454] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 12 months.

[0455] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least once every 12 months.

[0456] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg once every 12 months.

[0457] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg once every 12 months.

[0458] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 9 months; after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg once every 12 months.

[0459] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg once every 12 months.

[0460] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least once every 12 months.

[0461] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 3 months; after 6 months; or after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 12 months.

[0462] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 6 months; after 6 months; or after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 12 months.

[0463] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 9 months; after 9 months; or a third administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 12 months.

[0464] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0465] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 12 months.

[0466] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; after 6 months; or after 9 months; or after 12 months a third administration of the anti-TRBV9 antibody at a dose of 620 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0467] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; after 6 months; or after 9 months; or after 12 months a third administration of the anti-TRBV9 antibody at a dose of 620 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0468] In some embodiments of the present invention, the method includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; after 9 months; or after 12 months a third administration of the anti-TRBV9 antibody at a dose of 620 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0469] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0470] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 12 months.

[0471] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 625 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0472] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 625 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0473] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 625 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0474] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 625 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0475] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 3 months, a third administration of the anti-TRBV9 antibody at a dose of 630 mg after at least 6 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 12 months.

[0476] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 3 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 630 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0477] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 6 months; after 6 months; or after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 630 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0478] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 9 months; after 9 months; or after 12 months; a third administration of the anti-TRBV9 antibody at a dose of 630 mg; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0479] In some embodiments of the present invention, the method includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, a third administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 12 months.

[0480] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.03 - 10 mg / kg.

[0481] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.03 - 7 mg / kg.

[0482] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.3 - 10 mg / kg.

[0483] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.3 - 7 mg / kg.

[0484] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 1 - 7 mg / kg.

[0485] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 2 - 7 mg / kg.

[0486] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 3 - 7 mg / kg.

[0487] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 4 - 7 mg / kg.

[0488] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 5-7 mg / kg.

[0489] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 6-7 mg / kg.

[0490] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg.

[0491] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 7.5 mg / kg, or 8 mg / kg, or 8.5 mg / kg, or 9 mg / kg, or 9.5 mg / kg, or 10 mg / kg.

[0492] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3-12 months.

[0493] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3-12 months.

[0494] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 6-12 months.

[0495] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 6-12 months.

[0496] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 months; or at least once every 6 months; or at least once every 9 months; or at least once every 12 months.

[0497] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 months; or once every 6 months; or once every 9 months; or once every 12 months.

[0498] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 75-675 mg.

[0499] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 100-650 mg.

[0500] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 75 - 175 mg; or 200 - 300 mg; or 325 - 425 mg; or 450 - 650 mg; or 575 - 675 mg.

[0501] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 100 - 150 mg; or 225 - 275 mg; or 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg.

[0502] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 115 - 135 mg; or 240 - 260 mg; or 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg.

[0503] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

[0504] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 - 12 months.

[0505] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 - 12 months.

[0506] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 6 - 12 months.

[0507] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 6 - 12 months.

[0508] In some embodiments of the present invention, the anti-TRBV9 antibody is administered at least once every 3 months; or at least once every 6 months; or at least once every 9 months; or at least once every 12 months.

[0509] In some embodiments of the present invention, the anti-TRBV9 antibody is administered once every 3 months; or once every 6 months; or once every 9 months; or once every 12 months.

[0510] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 0.03 - 10 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a main dose of 0.03 - 10 mg / kg.

[0511] In some embodiments of the present invention, the use includes the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0512] In some embodiments of the present invention, the use includes the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0513] In some embodiments of the present invention, the use includes the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 0.03 - 10 mg / kg once every 9 months; or once every 12 months.

[0514] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 10 mg / kg every 12 months.

[0515] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 0.03 - 7 mg / kg at least 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at the main dose of 0.03 - 7 mg / kg.

[0516] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0517] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 6 months; or once every 9 months; or once every 12 months.

[0518] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg once every 9 months; or once every 12 months.

[0519] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.015 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.03 - 7 mg / kg every 12 months.

[0520] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 0.3 - 10 mg / kg at least 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out at least every 6 months at the main dose of 0.3 - 10 mg / kg.

[0521] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0522] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg every 6 months; or every 9 months; or every 12 months.

[0523] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg every 9 months; or every 12 months.

[0524] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 0.3 - 10 mg / kg every 12 months.

[0525] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 0.3 - 7 mg / kg at least 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out at least every 6 months at the main dose of 0.3 - 7 mg / kg.

[0526] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at the main dose of 0.3 - 7 mg / kg.

[0527] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at the main dose of 0.3 - 7 mg / kg.

[0528] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody every 9 months; or every 12 months at the main dose of 0.3 - 7 mg / kg.

[0529] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 0.3 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody every 12 months at the main dose of 0.3 - 7 mg / kg.

[0530] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 1 - 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least every 6 months at the main dose of 1 - 7 mg / kg.

[0531] In some embodiments, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5 - 3.5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 1 - 7 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out every 6 months; or every 9 months; or every 12 months at the main dose of 1 - 7 mg / kg.

[0532] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody every 6 months; or every 9 months; or every 12 months at the main dose of 1 - 7 mg / kg.

[0533] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is equal to half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody every 9 months; or every 12 months at the main dose of 1 - 7 mg / kg.

[0534] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 0.15 - 3.5 mg / kg, which is half of the main dose, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 1 - 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 1 - 7 mg / kg every 12 months.

[0535] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg at least 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 1 mg / kg at least every 6 months.

[0536] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 1 mg / kg.

[0537] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg 6 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 1 mg / kg.

[0538] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg 9 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out once every 9 months; or once every 12 months at a dose of 1 mg / kg.

[0539] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg 12 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out once every 12 months at a dose of 1 mg / kg.

[0540] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 2 mg / kg at least 3 months later, and the subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 2 mg / kg at least every 6 months.

[0541] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 2 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 2 mg / kg.

[0542] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 2 mg / kg.

[0543] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 2 mg / kg.

[0544] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 2 mg / kg.

[0545] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 3 mg / kg.

[0546] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 3 mg / kg.

[0547] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 3 mg / kg.

[0548] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 3 mg / kg.

[0549] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 3 mg / kg.

[0550] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is performed at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is performed at a dose of 4 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 4 mg / kg at least once every 6 months.

[0551] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is performed at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is performed at a dose of 4 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 4 mg / kg.

[0552] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 4 mg / kg.

[0553] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 4 mg / kg.

[0554] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 4 mg / kg.

[0555] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 5 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 5 mg / kg at least once every 6 months.

[0556] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 5 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 5 mg / kg.

[0557] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg 6 months later, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 5 mg / kg.

[0558] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg 9 months later, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 5 mg / kg.

[0559] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg 12 months later, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 5 mg / kg.

[0560] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 6 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 6 mg / kg at least once every 6 months.

[0561] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 6 mg / kg 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out once every 6 months; or once every 9 months; or once every 12 months at a dose of 6 mg / kg.

[0562] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 6 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 6 mg / kg.

[0563] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 6 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 6 mg / kg.

[0564] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 6 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 6 mg / kg.

[0565] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 7 mg / kg.

[0566] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 7 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 7 mg / kg.

[0567] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 7 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 7 mg / kg.

[0568] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 7 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 7 mg / kg.

[0569] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 7 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are at a dose of 7 mg / kg every 12 months.

[0570] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 8 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0571] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 8 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0572] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 8 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 8 mg / kg.

[0573] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 8 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 8 mg / kg.

[0574] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is carried out at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 9 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 9 mg / kg.

[0575] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 9 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 9 mg / kg.

[0576] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 9 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 9 mg / kg.

[0577] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 4.5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 9 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 9 mg / kg.

[0578] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is performed at a dose of 5 mg / kg, the second administration of the anti-TRBV9 antibody is performed at a dose of 10 mg / kg after 3 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 10 mg / kg.

[0579] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 10 mg / kg after 6 months, and subsequent administrations of the anti-TRBV9 antibody are once every 6 months; or once every 9 months; or once every 12 months at a dose of 10 mg / kg.

[0580] In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 10 mg / kg after 9 months, and subsequent administrations of the anti-TRBV9 antibody are once every 9 months; or once every 12 months at a dose of 10 mg / kg.

[0581] (viii) The first administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg, and the second... In some embodiments of the present invention, the first administration of the anti-TRBV9 antibody is at a dose of 5 mg / kg, the second administration of the anti-TRBV9 antibody is at a dose of 10 mg / kg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are once every 12 months at a dose of 10 mg / kg.

[0582] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 75 - 300 mg, the second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg is carried out at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg are carried out at least once every 6 months.

[0583] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 6 months; or once every 9 months; or once every 12 months.

[0584] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 6 months; or once every 9 months; or once every 12 months.

[0585] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 9 months; or once every 12 months.

[0586] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 325 - 675 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 325 - 675 mg once every 12 months.

[0587] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 100 - 275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg is carried out at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg are carried out at least once every 6 months.

[0588] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg once every 6 months; or once every 9 months; or once every 12 months.

[0589] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg once every 6 months; or once every 9 months; or once every 12 months.

[0590] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg 9 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg once every 9 months; or once every 12 months.

[0591] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 650 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 650 mg once every 12 months.

[0592] In one aspect, the present invention relates to the use of anti-TRBV9 antibodies for the treatment of diseases or disorders mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 100 - 150 mg; or 225 - 275 mg, and after at least 3 months, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg, and subsequent administrations of the anti-TRBV9 antibody are carried out at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 6 months.

[0593] In some embodiments of the present invention, the use comprises (i) the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 100 - 150 mg; or 225 - 275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 6 months; or

[0594] (ii) the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 100 - 150 mg; or 225 - 275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 9 months; or

[0595] (iii) the first administration of the anti-TRBV9 antibody to a subject in need thereof at a dose of 100 - 150 mg; or 225 - 275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg once every 12 months; or

[0596] (iv) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 6 months; or

[0597] (v) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 9 months; or

[0598] (vi) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 6 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months; or

[0599] (vii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 9 months; or

[0600] (viii) The first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months; or

[0601] (ix) The first administration of the anti-TRBV9 antibody is at a dose of 100 - 150 mg; or 225 - 275 mg for a subject in need thereof. The second administration of the anti-TRBV9 antibody is at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody are at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg every 12 months.

[0602] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody is carried out at a dose of 115 - 135 mg; or 240 - 260 mg for a subject in need thereof, the second administration of the anti-TRBV9 antibody is at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody are at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least every 6 months.

[0603] In some embodiments of the present invention, the use includes (i) the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg for a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 6 months; or

[0604] (ii) the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg for a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg after 3 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg every 9 months; or

[0605] (iii) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is after 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are once every 12 months; or

[0606] (iv) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are once every 6 months; or

[0607] (v) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are once every 9 months; or

[0608] (vi) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is after 6 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are once every 12 months; or

[0609] (vii) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are once every 9 months; or

[0610] (viii) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is given after 9 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are given once every 12 months; or

[0611] (ix) The first administration of the anti-TRBV9 antibody to a subject in need thereof is at a dose of 115 - 135 mg; or 240 - 260 mg. The second administration of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is given after 12 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are given once every 12 months.

[0612] In one aspect, the present invention relates to the use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg. The second administration of the anti-TRBV9 antibody at the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg is given after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg are given at least once every 6 months.

[0613] In some embodiments, the present invention relates to the use of an anti-TRBV9 antibody for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein (i) the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg for a first administration, and after 3 months, the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for a second administration, and the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for subsequent administrations every 6 months; or

[0614] (ii) the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg for a first administration, and after 3 months, the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for a second administration, and the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for subsequent administrations every 9 months; or

[0615] (iii) the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg for a first administration, and after 3 months, the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for a second administration, and the anti-TRBV9 antibody is administered at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg for subsequent administrations every 12 months; or

[0616] (iv) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg six months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every six months; or

[0617] (v) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg six months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every nine months; or

[0618] (vi) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, and the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg six months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every twelve months; or

[0619] (vii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 9 months; or

[0620] (viii) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 9 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months; or

[0621] (ix) The first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg every 12 months.

[0622] In some embodiments of the present invention, the use includes the first administration of the anti-TRBV9 antibody at a dose of 120 mg, the second administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 6 months.

[0623] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least once every 6 months.

[0624] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 6 months; or once every 9 months; or once every 12 months.

[0625] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 6 months; or once every 9 months; or once every 12 months.

[0626] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 9 months; or once every 12 months.

[0627] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg once every 12 months.

[0628] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least once every 6 months.

[0629] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 6 months; or once every 9 months; or once every 12 months.

[0630] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 6 months; or every 9 months; or every 12 months.

[0631] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 9 months; or every 12 months.

[0632] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 125 mg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg every 12 months.

[0633] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least every 6 months.

[0634] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0635] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0636] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0637] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 130 mg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0638] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg at least every 6 months.

[0639] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0640] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 6 months; or every 9 months; or every 12 months.

[0641] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 9 months; or every 12 months.

[0642] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 370 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 370 mg every 12 months.

[0643] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg at least once every 6 months.

[0644] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 6 months; or once every 9 months; or once every 12 months.

[0645] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 6 months; or once every 9 months; or once every 12 months.

[0646] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 9 months; or once every 12 months.

[0647] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 125 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 375 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 375 mg once every 12 months.

[0648] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg at least once every 6 months.

[0649] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0650] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 6 months; or every 9 months; or every 12 months.

[0651] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 9 months; or every 12 months.

[0652] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 130 mg based on the body weight of a subject of 30 to 50 kg, a second administration of the anti-TRBV9 antibody at a dose of 380 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 380 mg every 12 months.

[0653] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every 6 months.

[0654] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg every 6 months; or every 9 months; or every 12 months.

[0655] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 6 months; or once every 9 months; or once every 12 months.

[0656] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 9 months; or once every 12 months.

[0657] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0658] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least once every 6 months.

[0659] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0660] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0661] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 9 months; or once every 12 months.

[0662] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg every 12 months.

[0663] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least every 6 months.

[0664] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0665] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 6 months; or every 9 months; or every 12 months.

[0666] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0667] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0668] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg at least every 6 months.

[0669] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 6 months; or once every 9 months; or once every 12 months.

[0670] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 6 months; or once every 9 months; or once every 12 months.

[0671] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 9 months; or once every 12 months.

[0672] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 495 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 495 mg once every 12 months.

[0673] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg at least once every 6 months.

[0674] In some embodiments of the present invention, the use comprises a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0675] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 6 months; or once every 9 months; or once every 12 months.

[0676] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 9 months; or once every 12 months.

[0677] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 500 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 500 mg once every 12 months.

[0678] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg at least once every 6 months.

[0679] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 6 months; or once every 9 months; or once every 12 months.

[0680] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject weighing 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg once every 6 months; or once every 9 months; or once every 12 months.

[0681] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 9 months; or every 12 months.

[0682] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg based on the body weight of a subject of 51 to 89 kg, a second administration of the anti-TRBV9 antibody at a dose of 505 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 505 mg every 12 months.

[0683] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least every 6 months.

[0684] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0685] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 6 months; or every 9 months; or every 12 months.

[0686] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0687] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 245 mg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0688] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 6 months.

[0689] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0690] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg 6 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0691] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg 9 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 9 months; or every 12 months.

[0692] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 250 mg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg 12 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 12 months.

[0693] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg at least every 6 months.

[0694] In some embodiments of the present invention, the use comprises a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg 3 months later; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg every 6 months; or every 9 months; or every 12 months.

[0695] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 6 months; or once every 9 months; or once every 12 months.

[0696] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 9 months; or once every 12 months.

[0697] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 255 mg, a second administration of the anti-TRBV9 antibody at a dose of 630 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 630 mg once every 12 months.

[0698] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg at least once every 6 months.

[0699] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 6 months; or once every 9 months; or once every 12 months.

[0700] In some embodiments of the present invention, the use includes a first administration of the anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject of 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg once every 6 months; or once every 9 months; or once every 12 months.

[0701] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 9 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 9 months; or every 12 months.

[0702] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 245 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 620 mg after 12 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 620 mg every 12 months.

[0703] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after at least 3 months, and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg at least every 6 months.

[0704] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 3 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0705] In some embodiments of the present invention, the use includes a first administration of an anti-TRBV9 antibody at a dose of 250 mg based on the body weight of a subject weighing 90 to 150 kg, a second administration of the anti-TRBV9 antibody at a dose of 625 mg after 6 months; and subsequent administrations of the anti-TRBV9 antibody at a dose of 625 mg every 6 months; or every 9 months; or every 12 months.

[0706] In some embodiments of the present invention, the use includes a first administration of an a...

Claims

1. A method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03-10 mg / kg or 75-675 mg.

2. The method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor according to claim 1, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 0.03-7 mg / kg.

3. The method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor according to claim 1, comprising administering to a subject in need thereof an anti-TRBV9 antibody at a dose of 100-650 mg.

4. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 1-7 mg / kg.

5. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 3-7 mg / kg.

6. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 5-7 mg / kg.

7. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 75-175 mg; or 200-300 mg; or 325-425 mg; or 450-650 mg; or 575-675 mg.

8. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 100-150 mg; or 225-275 mg; or 350-400 mg; or 475-525 mg; or 600-650 mg.

9. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 115-135 mg; or 240-260 mg; or 365-385 mg; or 490-510 mg; or 615-635 mg.

10. The method according to claim 1, wherein the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg; or at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

11. The method according to any one of claims 1-10, wherein the anti-TRBV9 antibody is administered at least once every 3-12 months.

12. The method according to any one of claims 1-10, wherein the anti-TRBV9 antibody is administered at least once every 6-12 months.

13. The method according to any one of claims 1-10, wherein the anti-TRBV9 antibody is administered at least once every 3 months; or the anti-TRBV9 antibody is administered at least once every 6 months; or the anti-TRBV9 antibody is administered at least once every 9 months; or the anti-TRBV9 antibody is administered at least once every 12 months.

14. A method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, comprising (i) a first administration of an anti-TRBV9 antibody at a dose equal to half of the main dose, 0.5-5 mg / kg, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1-10 mg / kg at least once every 6 months; or (ii) a first administration of the anti-TRBV9 antibody at a dose of 75-300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 325-675 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 325-675 mg at least once every 6 months.

15. The method of treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor according to claim 14, comprising (i) a first administration of the anti-TRBV9 antibody at a dose equal to half of the main dose, 0.5-3.5 mg / kg, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1-7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1-7 mg / kg at least once every 6 months; or (ii) a first administration of the anti-TRBV9 antibody at a dose of 100-275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 350-650 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 350-650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 350-650 mg at least once every 12 months.

16. The method according to claim 14, comprising (i) a first administration of the anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg at least once every 6 months; or (ii) a first administration of the anti-TRBV9 antibody at a dose of 1 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg at least once every 6 months; or (iii) The first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg at least once every 6 months; or (iv) The first administration of the anti-TRBV9 antibody at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg at least once every 6 months; or (v) The first administration of the anti-TRBV9 antibody at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg at least once every 6 months.

17. The method according to claim 14, which comprises a first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 6 months.

18. The method according to claim 14, which comprises a first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least once every 6 months.

19. The method according to claim 14, which comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least once every 6 months.

20. A method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, comprising (i) a first administration of an anti-TRBV9 antibody at a dose equal to half of the main dose, 0.5 - 5 mg / kg, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 10 mg / kg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 10 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 10 mg / kg at least once every 12 months; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 75 - 300 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 325 - 675 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 325 - 675 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 325 - 675 mg at least once every 12 months.

21. The method for treating a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor according to claim 20, comprising (i) a first administration of an anti-TRBV9 antibody at a dose equal to half of the main dose, 0.5 - 3.5 mg / kg, to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 1 - 7 mg / kg at least once every 12 months; or (ii) a first administration of an anti-TRBV9 antibody at a dose of 100 - 275 mg to a subject in need thereof, a second administration of the anti-TRBV9 antibody at the main dose of 350 - 650 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at the main dose of 350 - 650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at the main dose of 350 - 650 mg at least once every 12 months.

22. The method according to claim 20, comprising (i) a first administration of an anti-TRBV9 antibody at a dose of 0.5 mg / kg, a second administration of the anti-TRBV9 antibody at a dose of 1 mg / kg at least 3 months later, a third administration of the anti-TRBV9 antibody at a dose of 1 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 1 mg / kg at least once every 12 months; or (ii) The first administration of the anti-TRBV9 antibody at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 2 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody at a dose of 2 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 2 mg / kg at least once every 12 months; or (iii) The first administration of the anti-TRBV9 antibody at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 3 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody at a dose of 3 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 3 mg / kg at least once every 12 months; or (iv) The first administration of the anti-TRBV9 antibody at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody at a dose of 5 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody at a dose of 5 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 5 mg / kg at least once every 12 months; or (v) The first administration of the anti-TRBV9 antibody at a dose of 3.5 mg / kg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody at a dose of 7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a dose of 7 mg / kg at least once every 12 months.

23. The method according to claim 20, which comprises the first administration of the anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg to a subject in need thereof, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 3 months later, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 12 months.

24. The method according to claim 20, which comprises the first administration of the anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least once every 6 months.

25. The method according to claim 20, which comprises a first administration of the anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, a third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least once every 12 months.

26. The method according to any one of claims 1, 14, 20, wherein the anti-TRBV9 antibody comprises: 1) A heavy chain variable domain, which comprises: (a) An HCDR1 having the amino acid sequence of SEQ ID NO:1, (b) An HCDR2 having the amino acid sequence of SEQ ID NO:2, and (c) An HCDR3 having an amino acid sequence selected from: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6; 2) A light chain variable domain, which comprises: (a) An LCDR1 having the amino acid sequence of SEQ ID NO:7, (b) An LCDR2 having the amino acid sequence of SEQ ID NO:8, and (c) An LCDR3 having the amino acid sequence of SEQ ID NO:

9.

27. The method according to claim 26, wherein the anti-TRBV9 antibody comprises: 1) A heavy chain variable domain, which comprises: (a) An HCDR1 having the amino acid sequence of SEQ ID NO:1, (b) An HCDR2 having the amino acid sequence of SEQ ID NO:2, and (c) An HCDR3 having the amino acid sequence of SEQ ID NO:4; 2) A light chain variable domain, which comprises: (a) An LCDR1 having the amino acid sequence of SEQ ID NO:7, (b) An LCDR2 having the amino acid sequence of SEQ ID NO:8, and (c) An LCDR3 having the amino acid sequence of SEQ ID NO:

9.

28. The method according to claim 26, wherein the anti-TRBV9 antibody is a full-length antibody and has a human IgG1, IgG2, IgG3 or IgG4 isotype.

29. The method according to claim 26, wherein the anti-TRBV9 antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID No: 14 and a light chain variable domain having the amino acid sequence of SEQ ID No: 17; or a heavy chain variable domain having the amino acid sequence of SEQ ID No: 15 and a light chain variable domain having the amino acid sequence of SEQ ID No:

17.

30. The method according to claim 26, wherein the anti-TRBV9 antibody comprises a heavy chain having the amino acid sequence of SEQ ID No: 22 and a light chain having the amino acid sequence of SEQ ID No: 25; or a heavy chain having the amino acid sequence of SEQ ID No: 23 and a light chain having the amino acid sequence of SEQ ID No:

25.

31. The method according to any one of claims 1, 14, 20, wherein the disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor is selected from the following: arthropathy, inflammatory bowel disease, eye disease, vasculitis, circulatory system disease, kidney disease, digestive system disease, lymphoproliferative disease.

32. The method according to any one of claims 1, 14, 20, wherein the disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor is selected from the following: spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel disease, undifferentiated oligoarthritis, juvenile spondylitis / arthritis associated with enthesitis, juvenile ankylosing spondylitis (arthritis associated with enthesitis), juvenile arthritis, undifferentiated juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behçet's disease, aortitis, aortic valve and / or mitral valve leaf fibrosis with regurgitation, rhythm disorder, conduction disorder, left ventricular dysfunction, pericarditis, myocarditis, IgA nephropathy, celiac disease, T cell lymphoma, T cell leukemia.

33. The method according to claim 32, wherein the spondyloarthritis is radiologically positive axial spondyloarthritis (ankylosing spondylitis), radiologically negative axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, undifferentiated peripheral spondyloarthritis.

34. The method according to claim 32, wherein the spondyloarthritis is radiological axial spondyloarthritis (ankylosing spondylitis) in patients with insufficient response to standard therapy, radiological non-axial spondyloarthritis in patients with insufficient response to standard therapy, axial spondyloarthritis in patients with insufficient response to standard therapy, peripheral spondyloarthritis in patients with insufficient response to standard therapy, psoriatic arthritis in patients with insufficient response to standard therapy, spondyloarthritis associated with inflammatory bowel disease in patients with insufficient response to standard therapy, reactive arthritis in patients with insufficient response to standard therapy, or undifferentiated peripheral spondyloarthritis in patients with insufficient response to standard therapy.

35. Use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.03 - 10 mg / kg or a dose of 75 - 675 mg.

36. Use of the anti-TRBV9 antibody according to claim 35 for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 0.03 - 7 mg / kg.

37. Use of the anti-TRBV9 antibody according to claim 35 for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein the anti-TRBV9 antibody is administered to a subject in need thereof at a dose of 100 - 650 mg.

38. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 1 - 7 mg / kg.

39. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 3 - 7 mg / kg.

40. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 5 - 7 mg / kg.

41. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 75 - 175 mg; or 200 - 300 mg; or 325 - 425 mg; or 450 - 650 mg; or 575 - 675 mg.

42. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 100 - 150 mg; or 225 - 275 mg; or 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg.

43. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 115 - 135 mg; or 240 - 260 mg; or 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg.

44. The use according to claim 35, wherein the anti-TRBV9 antibody is administered at a dose of 1 mg / kg, or 2 mg / kg, or 3 mg / kg, or 4 mg / kg, or 5 mg / kg, or 6 mg / kg, or 7 mg / kg; or at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg; or 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg.

45. The use according to any one of claims 35-44, wherein the anti-TRBV9 antibody is administered at least once every 3-12 months.

46. The use according to any one of claims 35-44, wherein the anti-TRBV9 antibody is administered at least once every 6-12 months.

47. The use according to any one of claims 35-44, wherein the anti-TRBV9 antibody is administered at least once every 3 months; or the anti-TRBV9 antibody is administered at least once every 6 months; or the anti-TRBV9 antibody is administered at least once every 9 months; or the anti-TRBV9 antibody is administered at least once every 12 months.

48. The use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein (i) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5-5 mg / kg, which is equal to half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 1-10 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at the main dose of 1-10 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 75-300 mg, the second administration of the anti-TRBV9 antibody is carried out at the main dose of 325-675 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at the main dose of 325-675 mg.

49. Use of the anti-TRBV9 antibody according to claim 48 for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein (i) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5 - 3.5 mg / kg, which is half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 1 - 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a main dose of 1 - 7 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody is carried out at a dose of 100 - 275 mg, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 350 - 650 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a main dose of 350 - 650 mg.

50. Use according to claim 48, wherein (i) the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 1 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 2 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 2 mg / kg; or (iii) the first administration of the anti-TRBV9 antibody is carried out at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 3 mg / kg; or (iv) the first administration of the anti-TRBV9 antibody is carried out at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 5 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 5 mg / kg; or (v) the first administration of the anti-TRBV9 antibody is carried out at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 7 mg / kg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 6 months at a dose of 7 mg / kg.

51. The use according to claim 48, which comprises a first administration of an anti-TRBV9 antibody at a dose of 100 - 150 mg; or 225 - 275 mg, a second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 6 months.

52. The use according to claim 48, which comprises a first administration of an anti-TRBV9 antibody at a dose of 115 - 135 mg; or 240 - 260 mg, a second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg at least once every 6 months.

53. The use according to claim 48, which comprises a first administration of an anti-TRBV9 antibody at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg for a subject in need thereof, a second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least 3 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg at least once every 6 months.

54. Use of an anti-TRBV9 antibody for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein (i) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5 - 5 mg / kg, which is half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 1 - 10 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a main dose of 1 - 10 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 12 months at a main dose of 1 - 10 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 75 - 300 mg, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 325 - 675 mg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a main dose of 325 - 675 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 12 months at a main dose of 325 - 675 mg.

55. Use of the anti-TRBV9 antibody according to claim 54 for the treatment of a disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor, wherein (i) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 0.5 - 3.5 mg / kg, which is half of the main dose, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 1 - 7 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a main dose of 1 - 7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 12 months at a main dose of 1 - 7 mg / kg; or (ii) the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 100 - 275 mg, the second administration of the anti-TRBV9 antibody is carried out at a main dose of 350 - 650 mg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a main dose of 350 - 650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 12 months at a main dose of 350 - 650 mg.

56. Use according to claim 54, wherein (i) the first administration of the anti-TRBV9 antibody is carried out at a dose of 0.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at least once every 12 months at a dose of 1 mg / kg; or (ii) The first administration of the anti-TRBV9 antibody is carried out at a dose of 1 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 2 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a dose of 2 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 2 mg / kg at least once every 12 months; or (iii) The first administration of the anti-TRBV9 antibody is carried out at a dose of 1.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a dose of 3 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 3 mg / kg at least once every 12 months; or (iv) The first administration of the anti-TRBV9 antibody is carried out at a dose of 2.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 5 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a dose of 5 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 5 mg / kg at least once every 12 months; or (v) The first administration of the anti-TRBV9 antibody for a subject in need thereof is carried out at a dose of 3.5 mg / kg, the second administration of the anti-TRBV9 antibody is carried out at a dose of 7 mg / kg at least 3 months later, the third administration of the anti-TRBV9 antibody is carried out at a dose of 7 mg / kg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody are carried out at a dose of 7 mg / kg at least once every 12 months.

57. The use according to claim 54, which comprises the first administration of the anti-TRBV9 antibody for a subject in need thereof at a dose of 100 - 150 mg; or 225 - 275 mg, the second administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 3 months later, the third administration of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 350 - 400 mg; or 475 - 525 mg; or 600 - 650 mg at least once every 12 months.

58. For the use according to claim 54, the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 115 - 135 mg; or 240 - 260 mg, the second administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is carried out at least 3 months later, the third administration of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg is carried out at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 365 - 385 mg; or 490 - 510 mg; or 615 - 635 mg are carried out at least once every 12 months.

59. For the use according to claim 54, the first administration of the anti-TRBV9 antibody to a subject in need thereof is carried out at a dose of 120 mg; or 125 mg; or 130 mg; or 245 mg; or 250 mg; or 255 mg, the second administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg is carried out at least 3 months later, the third administration of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg is carried out at least 6 months later, and subsequent administrations of the anti-TRBV9 antibody at a main dose of 370 mg; or 375 mg; or 380 mg; or 495 mg; or 500 mg; or 505 mg; or 620 mg; or 625 mg; or 630 mg are carried out at least once every 12 months.

60. For the use according to any one of claims 35, 48, 54, wherein the anti-TRBV9 antibody comprises: 1) A heavy chain variable domain, which comprises: (a) An HCDR1 having the amino acid sequence of SEQ ID NO:1, (b) An HCDR2 having the amino acid sequence of SEQ ID NO:2, and (c) An HCDR3 having an amino acid sequence selected from: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6; 2) A light chain variable domain, which comprises: (a) An LCDR1 having the amino acid sequence of SEQ ID NO:7, (b) An LCDR2 having the amino acid sequence of SEQ ID NO:8, and (c) An LCDR3 having the amino acid sequence of SEQ ID NO:

9.

61. For the use according to claim 60, wherein the anti-TRBV9 antibody comprises: 1) A heavy chain variable domain, which comprises: (a) An HCDR1 having the amino acid sequence of SEQ ID NO:1, (b) An HCDR2 having the amino acid sequence of SEQ ID NO:2, and (c) An HCDR3 having the amino acid sequence of SEQ ID NO:4; 2) A light chain variable domain, comprising: (a) An LCDR1 having the amino acid sequence of SEQ ID NO:7, (b) An LCDR2 having the amino acid sequence of SEQ ID NO:8, and (c) An LCDR3 having the amino acid sequence of SEQ ID NO:

9.

62. The use according to claim 60, wherein the anti-TRBV9 antibody is a full-length antibody and has a human IgG1, IgG2, IgG3 or IgG4 isotype.

63. The use according to claim 60, wherein the anti-TRBV9 antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID No:14 and a light chain variable domain having the amino acid sequence of SEQ ID No:17; or a heavy chain variable domain having the amino acid sequence of SEQ ID No:15 and a light chain variable domain having the amino acid sequence of SEQ ID No:

17.

64. The use according to claim 60, wherein the anti-TRBV9 antibody comprises a heavy chain having the amino acid sequence of SEQ ID No:22 and a light chain having the amino acid sequence of SEQ ID No:25; or a heavy chain having the amino acid sequence of SEQ ID No:23 and a light chain having the amino acid sequence of SEQ ID No:

25.

65. The use according to any one of claims 35, 48, 54, wherein the disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor is selected from the following: arthropathy, inflammatory bowel disease, eye disease, vasculitis, circulatory system disease, kidney disease, digestive system disease, lymphoproliferative disease.

66. The use according to any one of claims 35, 48, 54, wherein the disease or disorder mediated by T lymphocytes carrying the TRBV9 segment in the T cell receptor is selected from the following: spondyloarthritis, sacroiliitis associated with psoriasis, sacroiliitis associated with inflammatory bowel disease, undifferentiated oligoarthritis, juvenile spondylitis / arthritis associated with enthesitis, juvenile ankylosing spondylitis (arthritis associated with enthesitis), juvenile arthritis, undifferentiated juvenile arthritis, ulcerative colitis, Crohn's disease, non-infectious uveitis, anterior uveitis, Behcet's disease, aortitis, aortic valve and / or mitral valve leaflet fibrosis with regurgitation, rhythm disorder, conduction disorder, left ventricular dysfunction, pericarditis, myocarditis, IgA nephropathy, celiac disease, T cell lymphoma, T cell leukemia.

67. The use according to claim 66, wherein the spondyloarthritis is radiologically positive axial spondyloarthritis (ankylosing spondylitis), radiologically negative axial spondyloarthritis, axial spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, spondyloarthritis associated with inflammatory bowel disease, reactive arthritis, undifferentiated peripheral spondyloarthritis.

68. The use according to claim 66, wherein the spondyloarthritis is radiological axial spondyloarthritis (ankylosing spondylitis) in patients with insufficient response to standard therapy, radiological non-axial spondyloarthritis in patients with insufficient response to standard therapy, axial spondyloarthritis in patients with insufficient response to standard therapy, peripheral spondyloarthritis in patients with insufficient response to standard therapy, psoriatic arthritis in patients with insufficient response to standard therapy, spondyloarthritis associated with inflammatory bowel disease in patients with insufficient response to standard therapy, reactive arthritis in patients with insufficient response to standard therapy, or undifferentiated peripheral spondyloarthritis in patients with insufficient response to standard therapy.

Images